Navigation Links
Cepheid Announces Preliminary 2013 Second Quarter Results
Date:7/11/2013

ical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to revenues and earnings per share for the Second Quarter, projected future revenues for both the Third Quarter and Fiscal Year 2013, consistency of product availability and delivery, sales organization productivity, improving gross margins, execution of manufacturing operations, product sales under the High Burden Developing Country (HBDC) program, commercial test and commercial system sales, and resolution of manufacturing scale-up issues.  Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the Company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: our Second Quarter review process is not yet completed and actual Second Quarter results are subject to our standard quarterly close and review process; our ability to secure sufficient cartridge parts and increase manufacturing throughput of our cartridge production; our ability to manage our inventory levels; long sales cycles and variability in systems placements and reagent pull-through in the Company's HBDC program; our success in increasing commercial and HBDC sales and the effectiveness of our sales personnel; the performance and market acceptance of new products; sufficient customer demand, customer confidence in product availability and available capital budgets for our customers; our ability to develop new products and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites, including for Healthcare Associated Infections (HAIs); the Company's ability to successfully introduce and sell products in clinical markets other than HAIs; the rat
'/>"/>
SOURCE Cepheid
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cepheid Welcomes Executive Vice President of Global Operations
2. Cepheid Reports 2013 First Quarter Results
3. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
4. Cepheid Announces Board of Directors Changes
5. Cepheid Reports 2012 Second Quarter Results
6. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
7. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
8. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
9. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
10. Cepheid to Webcast Upcoming Financial Presentations
11. Cepheid Reports Fourth Quarter and Full Year 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 26, 2014 On January, 14, ... Baltimore and Washington D.C. science community to the UMBC ... event, sponsored by the Protein Society, will take place ... Center, Room 312. Through discussion, presentations and workshops, ... importance of proteins, their role in the industry and ...
(Date:11/26/2014)... Silicon Valley Electronic Data Capture (EDC) provider ... provider of clinical research and data management services to ... its CRO Partnership Program, Clinovo expands ClinCapture , ... , “We have found Clinovo’s ClinCapture to exceed our ... is both user friendly and easy to deploy. The ...
(Date:11/26/2014)... November 26, 2014 SoundConnect , ... is proud to announce that Darren Suders has joined ... Darren will drive the partner program ... experience. , Darren brings more than 10-years ... key roles in channel operations, from policy development, to ...
(Date:11/26/2014)... Theravalues Corporation annuncia con orgoglio il lancio di Theracurmin® ... Europe 2014 (dal 2 al 4 dicembre, ... con la maggiore biodisponibilità di sempre, con una combinazione ... norme europee. La curcumina è un pigmento ... longa ) che è stata associata con attività antiossidanti, ...
Breaking Biology Technology:RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3
... 2008 The American Ceramic Society and the ... released ACerS-NIST Phase Equilibria Diagrams CD-ROM Database (Version ... evaluated phase diagrams of ceramic systems such as ... chalcogenides, and features over 1,000 new diagrams. , ...
... Directors of Schering-Plough Corporation (NYSE: SGP ) today declared ... will be made on Feb. 27, 2009, to shareholders of record ... of Sept. 30, 2008, there were 1,626,234,628 common shares outstanding. ... today also declared a quarterly dividend of $3.75 per share on ...
... Dec. 10 Nuvelo, Inc.,(Nasdaq: ... the Phase 1 trial of,recombinant, secreted protein, ... Wnt,Therapeutics Program. This single-center, double-blind, placebo-controlled,single-ascending dose ... of a single intravenous (IV) administration of ...
Cached Biology Technology:The American Ceramic Society releases new ACerS-NIST phase equilibria diagrams CD-ROM database 2Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers 2Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers 3Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers 4Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers 5
(Date:11/7/2014)... , Nov. 7, 2014  In conjunction with the ... Police Departments, The Community Foundation of the Verdugos has ... DNA JUSTICE PROJECT," a $250,000 initiative to keep the ... phase. In its first six months of existence, the Lab ... evidence support for local law enforcement. "Because our ...
(Date:11/6/2014)... deaths occur because of metastasis, yet progress in ... slow. , "It,s been particularly challenging to design ... research fellow in systems biology at Harvard Medical ... until after they,ve already metastasized." , Gujral and ... should help researchers better understand how metastasis begins. ...
(Date:11/5/2014)... professor of biology in the UTSA College of ... nation selected to receive a two-year $300,00 National ... Research (EAGER). The funding supports President Obama,s BRAIN ... create new technology that will demystify complex brain ... in neuroscience are broken into the interactions of ...
Breaking Biology News(10 mins):Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Migration negation 2Migration negation 3UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
... Four million people die every year from respiratory diseases such as ... dangerous. What is more, the flu vaccine is not as effective ... reason for this is that with age the fire power of ... largely unknown. An international EU project led by the University of ...
... vitamin in an attempt to defeat drug screening tests may ... from The Children's Hospital of Philadelphia and The University of ... toxic side effects from taking large amounts of niacin, also ... drug tests. , Both adult patients suffered skin ...
... technique pioneered by Dr Amanda Hayes and her UNSW ... cells to airborne toxicants and measures cytotoxic effects. The ... a small diffusion chamber and then exposed to selected ... exposure, they can study cell growth and metabolism, and ...
Cached Biology News:Fighting influenza & co. with 40,000 blood samples 2Fighting influenza & co. with 40,000 blood samples 3Misusing vitamin to foil drug test may be toxic; plus, it doesn't work 2Soft-cell approach cuts animal tests 2Soft-cell approach cuts animal tests 3
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
APOPTAG® Plastic Coverslips are designed to be custom fitted to the specific APOPTAG® kit application. Each coverslip has 2.5 x 1 dimensions....
Human VEGF-D Biotinylated MAb (Clone 78923)...
Recombinant Mouse TGF-beta RII/(human) Fc Chimera, CF...
Biology Products: